β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction.

• Main Authors: XiaoXia eLiu, Sophie eTurban, Roderick N Carter, Shakil eAhmad, Lynne eRamage, Scott P Webster, Brian R Walker, Jonathan eSeckl, Nicholas Michael Morton
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2014-10-01
• Series: Frontiers in Endocrinology
• Subjects: Anti-Inflammatory Agents; Glucocorticoids; Inflammation; Streptozocin; type 1 diabetes; insulin secretion
• Online Access: http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00165/full

Progression and severity of Type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high doses employed clinically. In contrast, physiological-range elevation of glucocorticoid action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD1tg/+ mice). Here we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune destruction. MIP-HSD1tg/+ mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1tg/+ mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD1tg/+ islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. Glucocorticoid regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11β-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.